Heterobivalent drugs with GalR1 and GalR2 antagonist pharmacophors may specifically target the GalR1 and GalR2 binding pockets of the GalR1-GalR2 heteroreceptor complex, disrupt their function and represent a new strategy for treatment of depression and anxiety. Here, GALR1 is linked to depressive disorder.